<?xml version='1.0' encoding='utf-8'?>
<document id="10674711"><sentence text="Pharmacokinetics of selective serotonin reuptake inhibitors."><entity charOffset="30-39" id="DDI-PubMed.10674711.s1.e0" text="serotonin" /></sentence><sentence text="The five selective serotonin reuptake inhibitors (SSRIs), fluoxetine, fluvoxamine, paroxetine, sertraline, and citalopram, have similar antidepressant efficacy and a similar side effect profile"><entity charOffset="19-28" id="DDI-PubMed.10674711.s2.e0" text="serotonin" /><entity charOffset="58-68" id="DDI-PubMed.10674711.s2.e1" text="fluoxetine" /><entity charOffset="70-81" id="DDI-PubMed.10674711.s2.e2" text="fluvoxamine" /><entity charOffset="83-93" id="DDI-PubMed.10674711.s2.e3" text="paroxetine" /><entity charOffset="95-105" id="DDI-PubMed.10674711.s2.e4" text="sertraline" /><entity charOffset="111-121" id="DDI-PubMed.10674711.s2.e5" text="citalopram" /><pair ddi="false" e1="DDI-PubMed.10674711.s2.e0" e2="DDI-PubMed.10674711.s2.e0" /><pair ddi="false" e1="DDI-PubMed.10674711.s2.e0" e2="DDI-PubMed.10674711.s2.e1" /><pair ddi="false" e1="DDI-PubMed.10674711.s2.e0" e2="DDI-PubMed.10674711.s2.e2" /><pair ddi="false" e1="DDI-PubMed.10674711.s2.e0" e2="DDI-PubMed.10674711.s2.e3" /><pair ddi="false" e1="DDI-PubMed.10674711.s2.e0" e2="DDI-PubMed.10674711.s2.e4" /><pair ddi="false" e1="DDI-PubMed.10674711.s2.e0" e2="DDI-PubMed.10674711.s2.e5" /><pair ddi="false" e1="DDI-PubMed.10674711.s2.e1" e2="DDI-PubMed.10674711.s2.e1" /><pair ddi="false" e1="DDI-PubMed.10674711.s2.e1" e2="DDI-PubMed.10674711.s2.e2" /><pair ddi="false" e1="DDI-PubMed.10674711.s2.e1" e2="DDI-PubMed.10674711.s2.e3" /><pair ddi="false" e1="DDI-PubMed.10674711.s2.e1" e2="DDI-PubMed.10674711.s2.e4" /><pair ddi="false" e1="DDI-PubMed.10674711.s2.e1" e2="DDI-PubMed.10674711.s2.e5" /><pair ddi="false" e1="DDI-PubMed.10674711.s2.e2" e2="DDI-PubMed.10674711.s2.e2" /><pair ddi="false" e1="DDI-PubMed.10674711.s2.e2" e2="DDI-PubMed.10674711.s2.e3" /><pair ddi="false" e1="DDI-PubMed.10674711.s2.e2" e2="DDI-PubMed.10674711.s2.e4" /><pair ddi="false" e1="DDI-PubMed.10674711.s2.e2" e2="DDI-PubMed.10674711.s2.e5" /><pair ddi="false" e1="DDI-PubMed.10674711.s2.e3" e2="DDI-PubMed.10674711.s2.e3" /><pair ddi="false" e1="DDI-PubMed.10674711.s2.e3" e2="DDI-PubMed.10674711.s2.e4" /><pair ddi="false" e1="DDI-PubMed.10674711.s2.e3" e2="DDI-PubMed.10674711.s2.e5" /><pair ddi="false" e1="DDI-PubMed.10674711.s2.e4" e2="DDI-PubMed.10674711.s2.e4" /><pair ddi="false" e1="DDI-PubMed.10674711.s2.e4" e2="DDI-PubMed.10674711.s2.e5" /></sentence><sentence text=" They differ, however, in their pharmacokinetic properties" /><sentence text=" Under steady-state concentrations, their half-lives range between 1 and 4 days for fluoxetine (7 and 15 days for norfluoxetine) and between 21 (paroxetine) and 36 (citalopram) hr for the other SSRIs"><entity charOffset="84-94" id="DDI-PubMed.10674711.s4.e0" text="fluoxetine" /><entity charOffset="114-127" id="DDI-PubMed.10674711.s4.e1" text="norfluoxetine" /><entity charOffset="145-155" id="DDI-PubMed.10674711.s4.e2" text="paroxetine" /><pair ddi="false" e1="DDI-PubMed.10674711.s4.e0" e2="DDI-PubMed.10674711.s4.e0" /><pair ddi="false" e1="DDI-PubMed.10674711.s4.e0" e2="DDI-PubMed.10674711.s4.e1" /><pair ddi="false" e1="DDI-PubMed.10674711.s4.e0" e2="DDI-PubMed.10674711.s4.e2" /><pair ddi="false" e1="DDI-PubMed.10674711.s4.e1" e2="DDI-PubMed.10674711.s4.e1" /><pair ddi="false" e1="DDI-PubMed.10674711.s4.e1" e2="DDI-PubMed.10674711.s4.e2" /></sentence><sentence text=" Sertraline and citalopram show linear and fluoxetine, fluvoxamine, and paroxetine nonlinear pharmacokinetics"><entity charOffset="1-11" id="DDI-PubMed.10674711.s5.e0" text="Sertraline" /><entity charOffset="16-26" id="DDI-PubMed.10674711.s5.e1" text="citalopram" /><entity charOffset="43-53" id="DDI-PubMed.10674711.s5.e2" text="fluoxetine" /><entity charOffset="55-66" id="DDI-PubMed.10674711.s5.e3" text="fluvoxamine" /><entity charOffset="72-82" id="DDI-PubMed.10674711.s5.e4" text="paroxetine" /><pair ddi="false" e1="DDI-PubMed.10674711.s5.e0" e2="DDI-PubMed.10674711.s5.e0" /><pair ddi="false" e1="DDI-PubMed.10674711.s5.e0" e2="DDI-PubMed.10674711.s5.e1" /><pair ddi="false" e1="DDI-PubMed.10674711.s5.e0" e2="DDI-PubMed.10674711.s5.e2" /><pair ddi="false" e1="DDI-PubMed.10674711.s5.e0" e2="DDI-PubMed.10674711.s5.e3" /><pair ddi="false" e1="DDI-PubMed.10674711.s5.e0" e2="DDI-PubMed.10674711.s5.e4" /><pair ddi="false" e1="DDI-PubMed.10674711.s5.e1" e2="DDI-PubMed.10674711.s5.e1" /><pair ddi="false" e1="DDI-PubMed.10674711.s5.e1" e2="DDI-PubMed.10674711.s5.e2" /><pair ddi="false" e1="DDI-PubMed.10674711.s5.e1" e2="DDI-PubMed.10674711.s5.e3" /><pair ddi="false" e1="DDI-PubMed.10674711.s5.e1" e2="DDI-PubMed.10674711.s5.e4" /><pair ddi="false" e1="DDI-PubMed.10674711.s5.e2" e2="DDI-PubMed.10674711.s5.e2" /><pair ddi="false" e1="DDI-PubMed.10674711.s5.e2" e2="DDI-PubMed.10674711.s5.e3" /><pair ddi="false" e1="DDI-PubMed.10674711.s5.e2" e2="DDI-PubMed.10674711.s5.e4" /><pair ddi="false" e1="DDI-PubMed.10674711.s5.e3" e2="DDI-PubMed.10674711.s5.e3" /><pair ddi="false" e1="DDI-PubMed.10674711.s5.e3" e2="DDI-PubMed.10674711.s5.e4" /></sentence><sentence text=" SSRIs underlie an extensive metabolism with high interindividual variability, whereby cytochrome P450 (CYP) isoenzymes play a major role" /><sentence text=" Therefore, resulting blood concentrations are highly variable between individuals" /><sentence text=" Except for N-demethylated fluoxetine, metabolites of SSRIs do not contribute to clinical actions"><entity charOffset="27-37" id="DDI-PubMed.10674711.s8.e0" text="fluoxetine" /></sentence><sentence text=" Therapeutically effective blood concentrations are unclear so far, although there is evidence for minimal effective and upper-threshold concentrations that should not be exceeded" /><sentence text=" Paroxetine and, to a lesser degree, fluoxetine and norfluoxetine are potent inhibitors of CYP2D6 and fluvoxamine of CYP1A2 and CYP2C19"><entity charOffset="1-11" id="DDI-PubMed.10674711.s10.e0" text="Paroxetine" /><entity charOffset="37-47" id="DDI-PubMed.10674711.s10.e1" text="fluoxetine" /><entity charOffset="52-65" id="DDI-PubMed.10674711.s10.e2" text="norfluoxetine" /><entity charOffset="102-113" id="DDI-PubMed.10674711.s10.e3" text="fluvoxamine" /><pair ddi="false" e1="DDI-PubMed.10674711.s10.e0" e2="DDI-PubMed.10674711.s10.e0" /><pair ddi="false" e1="DDI-PubMed.10674711.s10.e0" e2="DDI-PubMed.10674711.s10.e1" /><pair ddi="false" e1="DDI-PubMed.10674711.s10.e0" e2="DDI-PubMed.10674711.s10.e2" /><pair ddi="false" e1="DDI-PubMed.10674711.s10.e0" e2="DDI-PubMed.10674711.s10.e3" /><pair ddi="false" e1="DDI-PubMed.10674711.s10.e1" e2="DDI-PubMed.10674711.s10.e1" /><pair ddi="false" e1="DDI-PubMed.10674711.s10.e1" e2="DDI-PubMed.10674711.s10.e2" /><pair ddi="false" e1="DDI-PubMed.10674711.s10.e1" e2="DDI-PubMed.10674711.s10.e3" /><pair ddi="false" e1="DDI-PubMed.10674711.s10.e2" e2="DDI-PubMed.10674711.s10.e2" /><pair ddi="false" e1="DDI-PubMed.10674711.s10.e2" e2="DDI-PubMed.10674711.s10.e3" /></sentence><sentence text=" This can give rise to drug-drug interactions that may have no effect, lead to intoxication, or improve the therapeutic response" /><sentence text=" These different pharmacokinetic properties of the five SSRIs, especially their drug-drug interaction potential, should be considered when selecting a distinct SSRI for treatment of depression or other disorders with a suggested dysfunction of the serotonergic system in the brain" /><sentence text="" /></document>